Apply now: feature your voice in our cell & gene therapy series
Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community?
We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice!
In a study by Hasan & Motwani (2025), the use of emicizumab, a medication for hemophilia A, was evaluated over a five-year period at a single center. The research focused on children with severe hemophilia A, both with and without inhibitors to factor VIII, a protein essential for blood clotting. The findings indicated that emicizumab is effective in promoting blood clotting and reducing bleeding episodes in these patients. The study provided valuable long-term data on the safety and efficacy of emicizumab, complementing previous clinical trials and real-world analyses.
While the study reinforced the positive impact of emicizumab on patient outcomes, it also highlighted the need for ongoing monitoring and research to fully understand the long-term implications of its use in children with hemophilia A. The research by Hasan and Motwani contributes to the growing body of evidence supporting emicizumab as a prophylactic treatment option for this patient population.
More Info 
Add to Calendar 